The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data

Objective: Schizophrenia is a multifactorial disorder. It is known that a combination of extensive multiple common alleles may be involved in its etiology, each contributing with a small to moderate effect, and, possibly, some rare alleles with a much larger effect size. We aimed to perform a systematic review of association studies between schizophrenia (and its subphenotypes) and polymorphisms in the CNR1 gene, which encodes cannabinoid receptors classically implicated in schizophrenia pathophysiology, as well as to present unpublished results of an association study in a Brazilian population. Methods: Two reviewers independently searched for eligible studies and extracted outcome data using a structured form. Papers were retrieved from PubMed and ISI Web of Knowledge using the search term schizophrenia in combination with CNR1 or CB1 or cannabinoid receptor. Twenty-four articles met our inclusion criteria. We additionally present data from a study of our own comparing 182 patients with schizophrenia and 244 healthy controls. Results: No consistent evidence is demonstrated. Conclusion: Some seemingly positive association studies stress the need for further investigations of the possible role of endocannabinoid genetics in schizophrenia

Synthesis, quality control and dosimetry of the radiopharmaceutical 18F-sodium fluoride produced at the Center for Development of Nuclear Technology - CDTN

18F-Sodium fluoride (Na18F) is a radiopharmaceutical used for diagnosis in nuclear medicine by positron emission tomography (PET) imaging. Bone scintigraphy is normally performed using 99mTc-MDP. However, 18F PET scans promise high quality imaging with increased resolution and improved sensitivity and specificity. In order to make available a tool for more specific studies of tumors and non-oncological diseases of bone tissue, the UPPR/CDTN team undertook the production and quality control of Na18F injectable solution with the physical-chemical, microbiological and biological characteristics recommended in the U.S. Pharmacopeia. Na18F radiochemical purity was 96.7 ± 1.3 %, with Rf= 0.026 ± 0.006. The product presented a pH of 5.3 ± 0.6, half life of 109.0 ± 0.8 minutes, endotoxin limit < 5.0 EU.mL-1 and no microbial contaminants. The biodistribution of Na18F was similar to that described in the literature, with a clearance of 0.19 mL.min-1 and distribution volume of 18.76 mL. The highest bone concentration (5.0 ± 0.5 %ID.g-1) was observed 20 minutes after injection. Na18F produced at the UPPR presented all the quality assurance requirements of the U.S. Pharmacopeia and can be safely used for clinical bone imaging.<br>O Fluoreto de sódio 18F (Na18F) é um radiofármaco empregado para diagnóstico através da Tomografia por Emissão de Pósitrons (PET). Cintilografias ósseas são normalmente obtidas utilizando-se 99mTc-MDP. Entretanto, o interesse pelo Na18F é crescente, principalmente devido à obtanção de imagens de elevada resolução. Com o objetivo de tornar disponível uma ferramenta mais específica para estudos de tumores e doenças não-oncológicas do tecido ósseo, o grupo da UPPR/CDTN implementou a produção e o controle de qualidade da solução injetável de Na18F com as características físico-química, microbiológica e biológica preconizadas pela farmacopéia. Sua pureza radioquímica foi de 96,7 ± 1,3 %, com Rf= 0,026 ± 0,006. O produto apresentou pH igual a 5,3 ± 0,6, tempo de meia-vida de 109,0 ± 0,8 minutos, limite de endotoxinas < 5,0 EU.mL-1 e ausência de microrganismos. O perfil de biodistribuição em camundongos foi semelhante ao disponível na literatura, com depuração igual a 0,19 mL.min-1 e volume de distribuição igual a 18,76 mL. A concentração máxima (5,0 ± 0,5 % DI.g-1) foi observada no osso 20 minutos após a injeção. O Na18F produzido na UPPR do CDTN apresentou os parâmetros de qualidade definidos na farmacopéia americana e pode ser usado com segurança para uso clínico em cintilografia óssea

Clinical and epidemiological aspects of children hospitalized with severe rotavirus-associated gastroenteritis in Salvador, BA, Brazil

Little is known about the epidemiology of severe rotavirus-associated gastroenteritis in Brazil. Given the morbidity associated with this condition and the importance of having detailed knowledge about the impact of rotavirus infection on the epidemiology of acute diarrhea in children, especially those with the most severe diarrheal conditions, we retrospectively reviewed the medical records of all pediatric patients admitted to a tertiary hospital in Salvador, Brazil, due to rotavirus-associated gastroenteritis during one year. It was observed that rotavirus was responsible for 15.6% of the hospitalizations caused by diarrhea and/or vomiting during the period of the study and that 87 of 218 (39.1%) patients seen at the emergency room with rotavirus-associated gastroenteritis needed to be hospitalized, comprising the population of our study. Most patients presented signs of dehydration, and 41% of them had metabolic acidosis. Most patients (79%) were between six months and four years of age and 72% of the cases occurred in June and July. Gastrointestinal symptoms were rarely present at the beginning of the clinical presentation, and they normally did not last for more than one week

Clinical and epidemiological aspects of children hospitalized with severe rotavirus-associated gastroenteritis in Salvador, BA, Brazil

Little is known about the epidemiology of severe rotavirus-associated gastroenteritis in Brazil. Given the morbidity associated with this condition and the importance of having detailed knowledge about the impact of rotavirus infection on the epidemiology of acute diarrhea in children, especially those with the most severe diarrheal conditions, we retrospectively reviewed the medical records of all pediatric patients admitted to a tertiary hospital in Salvador, Brazil, due to rotavirus-associated gastroenteritis during one year. It was observed that rotavirus was responsible for 15.6% of the hospitalizations caused by diarrhea and/or vomiting during the period of the study and that 87 of 218 (39.1%) patients seen at the emergency room with rotavirus-associated gastroenteritis needed to be hospitalized, comprising the population of our study. Most patients presented signs of dehydration, and 41% of them had metabolic acidosis. Most patients (79%) were between six months and four years of age and 72% of the cases occurred in June and July. Gastrointestinal symptoms were rarely present at the beginning of the clinical presentation, and they normally did not last for more than one week